Stelara（クローン病治療薬）：市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 16
3.3 Prognosis 17
3.4 Quality of Life 17
4 Disease Management 18
4.1 Treatment Overview 19
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Opportunity and Unmet Need 27
6.1 Overview 27
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 28
6.3 More Therapies for Anti-TNF-Refractory Patients 29
6.4 Unmet Needs Gap Analysis 30
6.5 Targeted Therapies 31
6.6 Predictive Tools for Early Diagnosis and Treatment 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 33
8 Stelara (ustekinumab) 36
8.1 Overview 36
8.2 Efficacy 37
8.3 Safety 39
8.4 Dosing and Formulation 40
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 41
8.7 Pricing and Reimbursement 41
8.8 SWOT Analysis 42
8.9 Forecast 42
9 Appendix 45
9.1 Bibliography 45
9.2 Abbreviations 48
9.3 Methodology 51
9.4 Forecasting Methodology 51
9.4.1 Diagnosed CD Patients 51
9.4.2 Percent Drug-Treated Patients 52
9.4.3 General Pricing Assumptions 52
9.4.4 Generic Erosion 54
9.4.5 Pricing of Pipeline agents 54
9.5 Physicians and Specialists Included in This Study 55
9.6 Primary Research – Prescriber Survey 57
9.7 About the Authors 58
9.7.1 Author/Reviewer 58
9.7.2 Global Head of Healthcare 58
9.8 About GlobalData 59
9.9 Disclaimer 59